Clinical Trial Update: Candin for the Treatment of Common Warts [Phase 3]

View source ↗

Summary

Phase 3 trial update reports that the Candin study for Verruca vulgaris (common warts) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Verruca Vulgaris

Drugs mentioned

• Candin

Snippet

Sponsor: Nielsen BioSciences, Inc. | Conditions: Common Warts (Verruca Vulgaris) | Phase 3 | Status: COMPLETED